Literature DB >> 18270241

Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance.

J L Newton1, D E J Jones, E Henderson, L Kane, K Wilton, A D Burt, C P Day.   

Abstract

OBJECTIVE: To quantify fatigue in non-alcoholic fatty liver disease (NAFLD), to determine whether perceived fatigue reflects impairment of physical function and to explore potential causes. PATIENTS AND METHODS: A cohort study was carried out on 156 consecutive patients with histologically proven NAFLD studied in two cohorts. Phase 1 determined the perceived fatigue experienced by NAFLD patients (assessed using the Fatigue Impact Scale (FIS)) in comparison with normal and liver disease controls, and the relationship to physical function (actigraphy). In phase 2, biological associations of fatigue in NAFLD were explored.
RESULTS: Fatigue was markedly higher in NAFLD patients than in controls (mean (SD) FIS 51 (38) vs 8 (12), p<0.001). NAFLD patients showed significantly lower physical activity over 6 days (7089 (2909) mean steps/day vs 8676 (2894), p = 0.02). A significant inverse correlation was seen between FIS and physical activity (r = 0.1, p = 0.02). Fatigue experienced by NAFLD patients was similar to that in primary biliary cirrhosis (n = 36) (FIS 64 (9) vs 61 (2), p = NS). No association was seen between FIS and biochemical and histological markers of liver disease severity or insulin resistance (homeostasis model assessment (HOMA)) (r < 0.005). Significant association was seen between fatigue severity and daytime somnolence (Epworth Sleepiness Scale) (r = 0.2, p < 0.001).
CONCLUSION: Fatigue is a significant problem in NAFLD, is similar in degree to that in primary biliary cirrhosis patients and is associated with impairment in physical function. Fatigue in NAFLD appears to be unrelated to either severity of underlying liver disease or insulin resistance, but is associated with significant daytime somnolence.

Entities:  

Mesh:

Year:  2008        PMID: 18270241     DOI: 10.1136/gut.2007.139303

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  50 in total

Review 1.  Physical activity for the prevention and treatment of metabolic disorders.

Authors:  Luca Montesi; Simona Moscatiello; Marcella Malavolti; Rebecca Marzocchi; Giulio Marchesini
Journal:  Intern Emerg Med       Date:  2013-05-09       Impact factor: 3.397

2.  Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial.

Authors:  Shira Zelber-Sagi; Assaf Buch; Hanny Yeshua; Nahum Vaisman; Muriel Webb; Gil Harari; Ofer Kis; Naomi Fliss-Isakov; Elena Izkhakov; Zamir Halpern; Erwin Santo; Ran Oren; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 3.  Effects of physical activity upon the liver.

Authors:  Roy J Shephard; Nathan Johnson
Journal:  Eur J Appl Physiol       Date:  2014-11-04       Impact factor: 3.078

4.  The auditory system of the goldfish (Carassius auratus): effects of intense acoustic stimulation.

Authors:  A N Popper; N L Clarke
Journal:  Comp Biochem Physiol A Comp Physiol       Date:  1976-01

Review 5.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

6.  Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

Authors:  Shira Zelber-Sagi; Muriel Webb; Nimer Assy; Laurie Blendis; Hanny Yeshua; Moshe Leshno; Vlad Ratziu; Zamir Halpern; Ran Oren; Erwin Santo
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 7.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

8.  Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease.

Authors:  Julia L Newton; Jessie Pairman; Katharine Wilton; David E J Jones; Christopher Day
Journal:  Clin Auton Res       Date:  2009-12       Impact factor: 4.435

9.  Nonalcoholic fatty liver disease: Disease and comorbidity--effects on quality of life.

Authors:  Giulio Marchesini; Giampaolo Bianchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

10.  Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease.

Authors:  K D Kistler; J Molleston; A Unalp; S H Abrams; C Behling; J B Schwimmer
Journal:  Aliment Pharmacol Ther       Date:  2009-10-23       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.